| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044687046 |
| P356 | DOI | 10.1038/NATURE08279 |
| P932 | PMC publication ID | 4119783 |
| P698 | PubMed publication ID | 19727076 |
| P5875 | ResearchGate publication ID | 26786391 |
| P50 | author | Neal G. Copeland | Q66818896 |
| Nancy A. Jenkins | Q66818899 | ||
| Jeannette M. Bonifas | Q107438263 | ||
| P2093 | author name string | Qing Li | |
| Scott C Kogan | |||
| Jeroen P Roose | |||
| Keiko Akagi | |||
| Judith Sebolt-Leopold | |||
| Kevin Shannon | |||
| Linda Wolff | |||
| Matthew Gorman | |||
| Luis Parada | |||
| Doan T Le | |||
| Doris Kim | |||
| Michael Crone | |||
| Sally Przybranowski | |||
| Ernesto Diaz-Flores | |||
| Kristen M Coakley | |||
| Mary Tran | |||
| Jennifer O Lauchle | |||
| Kegan Warner | |||
| Kimberly Krisman | |||
| P2860 | cites work | The selectivity of protein kinase inhibitors: a further update | Q24654622 |
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder | Q28508406 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| Hyperactive Ras in developmental disorders and cancer | Q29616397 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. | Q34410067 | ||
| A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms | Q34858364 | ||
| RTCGD: retroviral tagged cancer gene database | Q34923778 | ||
| Digital signaling and hysteresis characterize ras activation in lymphoid cells | Q34929087 | ||
| Focus on myeloproliferative diseases and myelodysplastic syndromes | Q35988519 | ||
| Inherited predispositions and hyperactive Ras in myeloid leukemogenesis | Q36302528 | ||
| A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes | Q37169157 | ||
| Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. | Q37351577 | ||
| Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells | Q40571427 | ||
| Regulation of Ras in lymphocytes: get a GRP. | Q45345580 | ||
| Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders | Q46134351 | ||
| Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders | Q46413091 | ||
| Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells | Q46486969 | ||
| Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. | Q53356315 | ||
| Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice | Q74314309 | ||
| Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone | Q79984705 | ||
| Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration | Q80194445 | ||
| P433 | issue | 7262 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 411-414 | |
| P577 | publication date | 2009-09-02 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras | |
| P478 | volume | 461 |
| Q45955739 | A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. |
| Q35692793 | A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice |
| Q30359787 | A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type |
| Q39437389 | Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis |
| Q34339010 | Activation of the MEK-S6 pathway in high-grade ovarian cancers |
| Q33900906 | Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas |
| Q35788976 | Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth |
| Q38084235 | Cancer of mice and men: old twists and new tails |
| Q37220129 | Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition |
| Q35872763 | Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice |
| Q33685977 | Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm |
| Q54978251 | Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. |
| Q92254021 | Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models |
| Q47252408 | Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity |
| Q36928333 | Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo |
| Q92914123 | Evaluation of ERK as a therapeutic target in acute myelogenous leukemia |
| Q38778367 | Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. |
| Q34332175 | Genetically engineered mouse models of PI3K signaling in breast cancer |
| Q34138263 | Harnessing transposons for cancer gene discovery |
| Q34667782 | Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus |
| Q93003265 | High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions |
| Q39476025 | High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. |
| Q37065678 | How genetically engineered mouse tumor models provide insights into human cancers |
| Q51406708 | Identifying dynamical bottlenecks of stochastic transitions in biochemical networks. |
| Q35733735 | Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras |
| Q26851000 | Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation |
| Q38715792 | KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer |
| Q89748170 | Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia |
| Q34421363 | Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia |
| Q36497139 | MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. |
| Q46113055 | Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. |
| Q34052520 | Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia |
| Q39235100 | Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia |
| Q61812459 | Murine Models of Acute Myeloid Leukaemia |
| Q41959338 | Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice |
| Q54976643 | Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. |
| Q42662364 | Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. |
| Q35613659 | Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner |
| Q34575699 | Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. |
| Q36150711 | Non-germline genetically engineered mouse models for translational cancer research |
| Q42438728 | Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. |
| Q34023887 | Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors |
| Q33917204 | NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis |
| Q30438898 | Optimizing biologically targeted clinical trials for neurofibromatosis. |
| Q36647433 | PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia |
| Q84322701 | Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by |
| Q27852623 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. |
| Q34737521 | Preclinical efficacy of MEK inhibition in Nras-mutant AML. |
| Q33646519 | Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target |
| Q38227885 | Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting |
| Q38205441 | RasGRP Ras guanine nucleotide exchange factors in cancer |
| Q100605969 | RasGRP1 induces autophagy and transformation-associated changes in primary human keratinocytes |
| Q34203989 | RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype |
| Q35083742 | Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q90347538 | SPRED1 Is Downregulated and a Prognostic Biomarker in Adult Acute Myeloid Leukemia |
| Q39351060 | Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency |
| Q37304113 | Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency |
| Q24313621 | Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1 |
| Q36497201 | Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice |
| Q27022852 | Targeted therapies in development for non-small cell lung cancer |
| Q36352506 | Targeting oncogenic Ras signaling in hematologic malignancies |
| Q34227509 | The NF1 gene revisited - from bench to bedside |
| Q39383689 | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies |
| Q58792261 | Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma |
| Q42805287 | Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis. |
| Q24607185 | Transposon-based screens for cancer gene discovery in mouse models |
| Q34438500 | Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R |
| Q33607833 | Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy |
| Q33943271 | Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer |
Search more.